JPH03153627A - Medicament containing swellfish poison as pharmaceutically effective component, its preparation and extraction of said swellfish poison - Google Patents
Medicament containing swellfish poison as pharmaceutically effective component, its preparation and extraction of said swellfish poisonInfo
- Publication number
- JPH03153627A JPH03153627A JP1293622A JP29362289A JPH03153627A JP H03153627 A JPH03153627 A JP H03153627A JP 1293622 A JP1293622 A JP 1293622A JP 29362289 A JP29362289 A JP 29362289A JP H03153627 A JPH03153627 A JP H03153627A
- Authority
- JP
- Japan
- Prior art keywords
- toxin
- liquid
- filter
- fugu
- ovary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 238000000605 extraction Methods 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- 241001441724 Tetraodontidae Species 0.000 title 2
- 239000002574 poison Substances 0.000 title 2
- 231100000614 poison Toxicity 0.000 title 2
- 239000003053 toxin Substances 0.000 claims abstract description 126
- 231100000765 toxin Toxicity 0.000 claims abstract description 126
- 239000007788 liquid Substances 0.000 claims abstract description 87
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 60
- 210000001672 ovary Anatomy 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 32
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims abstract description 7
- 108700012359 toxins Proteins 0.000 claims description 119
- 241001441723 Takifugu Species 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 10
- 206010003119 arrhythmia Diseases 0.000 abstract description 6
- 230000006793 arrhythmia Effects 0.000 abstract description 6
- 239000002917 insecticide Substances 0.000 abstract description 6
- 238000010353 genetic engineering Methods 0.000 abstract description 5
- 239000000730 antalgic agent Substances 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 241001627955 Tetraodon lineatus Species 0.000 abstract 2
- 239000006228 supernatant Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010052164 Sodium Channels Proteins 0.000 description 2
- 102000018674 Sodium Channels Human genes 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001481760 Erethizon dorsatum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000488583 Panonychus ulmi Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- -1 painkillers Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、河豚毒素を有効成分とする薬剤及びその製造
方法並びに河豚毒素の抽出方向に関し、高純度の河豚毒
素により、ｉｆｔｆｔ玉子工学いられる生花試剤（試薬
）、不整脈の治療薬鎮痛剤、殺虫剤等に供するものであ
る。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a drug containing fugu toxin as an active ingredient, a method for producing the same, and a method for extracting fugu toxin. It is used for fresh flower reagents (reagents), arrhythmia remedies, analgesics, insecticides, etc.
従来、河豚の卵巣が極めて強い毒素を有していることは
知られているが、これを有効に利用することは行われて
いない、このため１食用に供される一部の種類のものを
除いては、漁獲された河豚を廃棄している無駄な現状に
ある。It has been known that the ovaries of fugu have an extremely strong toxin, but this has not been effectively utilized. The current situation is that the fish that are caught are discarded, which is wasteful.
この点について１本発明者は、河豚の毒素が多くの用途
を持ち得ることを知見し、実験の繰返しにより、これが
種々の薬剤１例えば、遺伝子工学に用いられる生花試剤
（試薬）、不整脈の治療薬、鎮痛剤、殺虫剤等に有効で
あることを発見した。In this regard, the inventor has found that the toxin of the fugu can have many uses, and through repeated experiments, it has been found that it can be used in various drugs, such as fresh flower reagents used in genetic engineering, and the treatment of arrhythmias. It was discovered that it is effective in medicines, painkillers, insecticides, etc.
また９本発明者は、河豚の卵巣から毒素を得るに際し１
種々の方法を研究し試験したが、永年の成果により、そ
の最良の方法を知得するに至った。9 In addition, the present inventor discovered that 1
We have researched and tested various methods, and after many years of research, we have come to know the best method.
そこで１本発明の薬剤は、河豚の卵巣から抽出した毒素
を有効成分とすることを特徴とする。Therefore, one feature of the drug of the present invention is that the active ingredient is a toxin extracted from the ovaries of river pigs.
また１本発明の河豚毒素を有効成分とする薬剤の製造方
法は、河豚の卵巣を液体に浸漬することにより該卵巣中
の毒素を液体中に抽出せしめた後、該液体より前記毒素
を分離し、該毒素を調製して薬剤となすことを特徴とす
る。In addition, the method for producing a drug containing fugu toxin as an active ingredient of the present invention involves immersing the ovary of a fugu in a liquid to extract the toxin in the ovary into the liquid, and then separating the toxin from the liquid. , characterized in that the toxin is prepared and used as a drug.
前記薬剤の製造方法に関して５本発明の第二の発明は、
河豚の卵巣を液体に浸漬し、該液体中に前記卵巣中の毒
素を抽出せしめる抽出工程と；前記液体より不要物を除
去し、毒素を含有した清液を分離する清液生成工程と；
前記清液をフィルタに透過せしめ該フィルタ中に毒素を
捕獲せしめた後、フィルタより毒素を取出し毒素のみを
得る毒素生成工程と；前記毒素を調製して薬剤とする調
製工程と；から成ることを特徴とする。5 Regarding the method for producing the drug, the second invention of the present invention includes:
an extraction step of immersing the ovary of a fugu in a liquid and extracting toxins in the ovary into the liquid; a liquid production step of removing unnecessary substances from the liquid and separating a liquid containing the toxin;
A toxin generation step in which the liquid is passed through a filter to trap toxins in the filter, the toxin is removed from the filter to obtain only the toxin; and a preparation step in which the toxin is prepared as a drug. Features.
また、前記薬剤の製造方法に関して１本発明の第三の発
明は、河豚の卵巣を液体に浸漬し該液体中に卵巣中の毒
素を抽出せしめる抽出工程と；前記液体から不要固形物
を除去して第一次清液を分離する第一次清液生成工程と
；前記第一次清液に含有せしめられた蛋白を除去して第
二次清液を分離する第二次清液生成工程と一前記第二次
清液をフィルタに透過せしめ該フィルタ中に毒素を捕獲
せしめた後、該フィルタを酢酸液により洗浄することに
より毒素を含有した酢酸液を得る毒素溶液生成工程と；
前記毒素溶液を弱アルカリ性に調整して毒素と酢酸を分
離し、毒素のみを得る毒素生成工程と：前記毒素を調製
して薬剤とする調製工程と；から成ることを特徴とする
。Regarding the method for producing the drug, a third invention of the present invention includes an extraction step of immersing the ovary of a fugu in a liquid and extracting toxins in the ovary into the liquid; and removing unnecessary solid matter from the liquid. a first clear liquid generation step in which a first clear liquid is separated; a second clear liquid generation step in which proteins contained in the first clear liquid are removed and a second clear liquid is separated; (a) a toxin solution generation step in which an acetic acid solution containing toxins is obtained by passing the second liquid liquid through a filter to trap toxins in the filter, and then washing the filter with an acetic acid solution;
The present invention is characterized by comprising: a toxin generation step in which the toxin solution is adjusted to be slightly alkaline and the toxin and acetic acid are separated to obtain only the toxin; and a preparation step in which the toxin is prepared as a drug.
更に１本発明の河豚毒素の抽出方法は、河豚の卵巣を液
体に浸漬することにより該卵巣中の毒素を液体中に抽出
せしめた後、該液体より前記毒素を分離することを特徴
とする。Furthermore, the method for extracting fugu toxin of the present invention is characterized in that the toxin in the ovary is extracted into the liquid by immersing the ovary of the fugu in a liquid, and then the toxin is separated from the liquid.
前記河豚毒素の抽出方法に関して１本発明の第二の発明
は、河豚の卵巣を液体に浸漬し、該液体中に前記卵巣中
の毒素を抽出せしめる抽出工程と；前記液体より不要物
を除去し、毒素を含有した清液を分離する清液生成工程
と；前記清液をフィルタに透過せしめ該フィルタ中に毒
素を捕獲せしめた後、フィルタより毒素を取出し毒素の
みを得る毒素生成工程と；から成ることを特徴とする。Regarding the method for extracting the Fugu toxin, the second aspect of the present invention includes an extraction step of immersing the ovary of the Fugu in a liquid and allowing the toxin in the ovary to be extracted into the liquid; and removing unnecessary substances from the liquid. , a fresh liquid production step of separating a fresh liquid containing toxins; a toxin generation step of passing the fresh liquid through a filter to trap the toxins in the filter, and then extracting the toxins from the filter to obtain only the toxins; It is characterized by becoming.
また、前記河豚毒素の抽出方法に関して１本発明の第三
の発明は、河豚の卵巣を液体に浸漬し、該液体中に卵巣
中の毒素を抽出せしめる抽出工程と；前記液体から不要
固形物を除去して第一次清液を分離する第一次清液生成
工程と；前記第一次清液に含有せしめられた蛋白を除去
して第二次清液を分離する第二次清液生成工程と；前記
第二次清液をフィルタに透過せしめ該フィルタ中に毒素
を捕獲せしめた後、該フィルタを酢酸液により洗浄する
ことにより毒素を含有した酢酸液を得る毒素溶液生成工
程と；前記毒素溶液を弱アルカリ性に調整して毒素と酢
酸を分離し、毒素のみを得る毒素生成工程と：から成る
ことを特徴とする。Regarding the method for extracting the fugu toxin, a third aspect of the present invention includes an extraction step of immersing the ovaries of the fugu in a liquid and allowing the toxin in the ovaries to be extracted into the liquid; and removing unnecessary solids from the liquid. a first clear liquid production step of removing and separating a first clear liquid; and a second clear liquid generation step of removing proteins contained in the first clear liquid and separating a second clear liquid. a step of producing a toxin solution in which an acetic acid solution containing toxins is obtained by passing the secondary liquid through a filter to trap toxins in the filter, and then washing the filter with an acetic acid solution; It is characterized by consisting of a toxin generation step in which the toxin solution is adjusted to be slightly alkaline and the toxin and acetic acid are separated to obtain only the toxin.
本発明の河豚毒素の抽出方法は、以下に説明する抽出工
程−第一次清液生成工程−第二次清液抽出工程一毒素捕
獲工程−毒素溶液生成工程−毒素生成工程から構成され
ている。そして本発明の河豚毒素を有効成分とする薬剤
の製造方法は、前記抽出方法に加えて、該抽出方法によ
り得られた高純度の毒素を調製して薬剤とする調製工程
を構成する。而して、薬剤は、遺伝子工学に用いられる
生花試剤（試薬）、不整脈の治療薬、鎮痛剤、殺虫剤等
に有効に用いることができる。The method for extracting fugu toxin of the present invention is comprised of the following steps: extraction step, first liquid generation step, second liquid extraction step, toxin capture step, toxin solution generation step, and toxin generation step. . The method for producing a drug containing fugu toxin as an active ingredient of the present invention includes, in addition to the above extraction method, a preparation step of preparing a highly purified toxin obtained by the extraction method to use it as a drug. Thus, the drug can be effectively used as a fresh flower reagent used in genetic engineering, a therapeutic drug for arrhythmia, an analgesic, an insecticide, and the like.
以下に、前記工程を順を追って説明する。Below, the steps will be explained step by step.
（抽出工程）
河豚の卵巣として新鮮で破れていないものを選別し、該
卵巣を水中に浸漬する。卵巣と水の割合は、卵巣１０ｋ
ｇに対して水３０ｋｇとし、浸漬時間は、２日間程度と
する。(Extraction step) Fresh and unbroken ovaries of Fugu are selected, and the ovaries are immersed in water. The ratio of ovary to water is ovary 10k.
The amount of water is 30 kg per g, and the immersion time is about 2 days.
（第一次清液生成工程） 前記水及び卵巣を遠心分離機に投入し、 ｉｏ、。(First liquid generation process) Pour the water and ovaries into a centrifuge, io.
ＱＱｒｐｍ、で８時間、遠心分離を行う。Centrifuge at QQrpm for 8 hours.
前記遠心回転により水中には卵巣の固形片が混入される
ため、水を濾過することにより前記不要固形物を除去し
、第一次清液を得る。Since solid pieces of ovary are mixed into the water due to the centrifugal rotation, the unnecessary solids are removed by filtering the water to obtain a primary clear liquid.
（第二次清液生成工程）
前記により得られた第一次清液を８０℃にて加熱し、第
一次清液中に含有されている蛋白を卵の白身状になるま
で凝固させ、水を濾過することにより前記蛋白を除去し
、第二次清液を得る。(Second clear liquid generation step) The primary clear liquid obtained above is heated at 80°C to coagulate the proteins contained in the first clear liquid until it becomes egg white-like. The protein is removed by filtering the water to obtain a second clear liquid.
（毒素捕獲工程）
前記により得られた第二次清液をフィルタに透過せしめ
該フィルタ中に毒素を捕獲せしめる。(Toxin Capture Step) The secondary liquid obtained above is passed through a filter to trap toxins in the filter.
このフィルタは９活性炭を柱状に成形したちのであり、
前記第二次清液を柱状フィルタの軸方向に流下せしめた
とき、１時間当たり４ ｋｇの第二次清液を透過せしめ
る。この第二次清液透過によりフィルタ中に毒素が付着
しつつ捕獲され。This filter is made of activated carbon formed into a column shape.
When the secondary liquid is allowed to flow down in the axial direction of the columnar filter, 4 kg of the secondary liquid per hour is allowed to pass through. Due to this second liquid permeation, toxins are captured while adhering to the filter.
毒素を除去された水はフィルタを流下して廃棄される。The toxin-free water flows down the filter and is disposed of.
（毒素溶液生成工程） 前記毒素を捕獲したフィルタを酢酸溶液にて洗浄する。(Toxin solution generation process) The filter containing the toxin is washed with an acetic acid solution.
これにより毒素はフィルタから洗い落とされ、酢酸溶液
中に混入し、毒素溶液が得られる。This washes the toxins from the filter and mixes them into the acetic acid solution, yielding a toxin solution.
（毒素生成工程） 前記毒素溶液を薄膜蒸発器を用いて加熱し。(Toxin generation process) The toxin solution is heated using a thin film evaporator.
水分を１００％蒸発せしめ、酢酸と毒素のみから成る高
純度の毒素溶液を得る。Evaporate 100% of the water to obtain a highly pure toxin solution consisting only of acetic acid and toxin.
次いで、この高純度の毒素溶液のＰ ［（をカセイソー
ダを用いて弱アルカリ性（ＰＨ９程度）に調整し、毒素
と酢酸を分離せしめる０分ｋＩシた毒素は酢酸中に沈澱
するので、該沈澱物を酢酸中から取出し、酢酸は廃棄す
る。Next, this highly purified toxin solution was adjusted to weak alkalinity (about pH 9) using caustic soda and heated for 0 minutes to separate the toxin and acetic acid. is removed from the acetic acid and the acetic acid is discarded.
この沈澱物は白色粉状の毒素粗削である。This precipitate is white powdery toxin residue.
その後、この毒素粗削を、加熱した後、１日間程度、冷
凍干燥することにより、結晶体の純粋毒素が得られる。Thereafter, the rough toxin is heated and freeze-dried for about one day to obtain pure toxin in the form of crystals.
（毒素の収率及び純度等）
上述したような１０ｋｇの河豚卵巣と３０ｋｇの水によ
り、最終的に得られる純粋毒素は４０■又はそれ以上で
ある。この毒素は、純度が９９％に達し、Ｃ＝４０．８
４％、Ｈ＝５．４３％。(Yield and Purity of Toxin, etc.) With 10 kg of Fugu ovary and 30 kg of water as described above, the final amount of pure toxin obtained is 40 μg or more. This toxin reaches 99% purity and C=40.8
4%, H=5.43%.
Ｎ＝１２．８５％であることが確認された。It was confirmed that N=12.85%.
（薬剤調製工程）
以上の毒素を薬剤として用いるには、適宜公知の方法に
従い調製する。(Drug Preparation Step) In order to use the above toxin as a drug, it is prepared according to an appropriate known method.
（薬剤の用途）
本発明の薬剤の第一の用途は、遺伝子工学に用いられる
生花試剤（試薬）１即ち、細胞膜ナトリウムＣｈａｎｎ
ｅｌ （通路）の連通性の研究に用いることができる。(Applications of the drug) The first use of the drug of the present invention is the fresh flower reagent (reagent) 1 used in genetic engineering, that is, cell membrane sodium Chann.
It can be used to study the connectivity of el (passage).
この場合、９６％以上の高純度の河豚毒素を用い、試薬
の剤型としては、含増溶剤（早く溶ける薬剤を含む剤型
）又は無増溶剤の何れの剤型としても良い、これにより
細胞膜ナトリウムＣｈａｎｎｅｌ の連通性の研究に資
することができ、ナトリウムＣｈａｎｎｅｌ と関連す
る病気の治療に役立つ。In this case, Fugu toxin with a high purity of 96% or higher is used, and the reagent formulation may be either a solvent-enriched formulation (a formulation containing a drug that dissolves quickly) or a solvent-free formulation. It can contribute to research on the connectivity of sodium channels and is useful for the treatment of diseases related to sodium channels.
本発明の薬剤の第二の用途は、不整脈の治療薬である。A second use of the drug of the present invention is as a therapeutic agent for arrhythmia.
この場合、９９％の高純度の河豚毒素を用いる。剤型は
、■カプセル、■錠剤、■注射剤型、■長期効能削型、
の何れとすることも可能である。In this case, 99% high purity Fugu toxin is used. Dosage forms are ■capsule, ■tablet, ■injection, ■long-term efficacy,
It is also possible to use either of the following.
本発明の薬剤の第三の用途は、鎮痛剤である。A third use of the medicament of the invention is as an analgesic.
河豚毒素の純度、剤型は、前記第二の用途に述べたもの
と同様である１本発明の鎮痛剤は、しｎ床試験の結果、
癌末期の病人に有効な鎮痛効果があり、しかも副作用の
ないことを６１１ Ｅ’２することができた。The purity and dosage form of the Fugu toxin are the same as those described in the second use.1 The analgesic of the present invention has the following results from the bed test:
611 E'2 was able to demonstrate that it has an effective analgesic effect on terminally ill patients with cancer and has no side effects.
本発明の薬剤の第四の用途は、農業用殺虫剤であり、棉
紅蜘蛛（棉を食いあらず蜘蛛）を駆逐する農薬として有
効である。この場合は１比較的低線度の河豚毒素で足り
る。剤型は、粉剤、粒状剤、噴霧剤１錠体剤、の何れと
することも可能である。A fourth use of the drug of the present invention is as an agricultural insecticide, and it is effective as a pesticide for expelling cotton red spiders (spiders that do not eat cotton). In this case, a relatively low-grade fugu toxin is sufficient. The dosage form can be any of powder, granule, and spray tablet.
特許請求の範囲第１項に記載の本発明によれば、河豚の
卵巣を有効利用することにより、遺伝子工学に用いられ
る生花試剤（試薬）、不整脈の治療薬、鎮痛剤、殺虫剤
等の薬剤を提供することができる。According to the present invention as set forth in claim 1, by effectively utilizing the ovaries of the fugu, fresh flower reagents (reagents) used in genetic engineering, drugs for treating arrhythmia, analgesics, insecticides, and other drugs can be produced. can be provided.
特許請求の範囲第２項ないし第４項に記載の本発明によ
れば、高純度の河豚毒素から成る薬剤を製造することが
可能になる。According to the present invention as set forth in claims 2 to 4, it is possible to produce a drug consisting of highly purified kawagu toxin.
特許請求の範囲第５項ないし第７項に記載の本発明によ
れば、前記薬剤に用いる河豚毒素を得るに際し、河豚の
卵巣から該毒素を高純度で高収率にて抽出することが可
能になる。According to the present invention as set forth in claims 5 to 7, when obtaining the toxin used in the drug, it is possible to extract the toxin from the ovaries of the porcupine with high purity and high yield. become.
１８18
Claims (7)
剤。(1) A drug whose active ingredient is a toxin extracted from the ovaries of river pigs.
の毒素を液体中に抽出せしめた後、該液体より前記毒素
を分離し、該毒素を調製して薬剤となすことを特徴とす
る河豚毒素を有効成分とする薬剤の製造方法。(2) The toxin in the ovary is extracted into the liquid by immersing the ovary of the river pig in a liquid, and then the toxin is separated from the liquid, and the toxin is prepared as a drug. A method for producing a drug containing fugu toxin as an active ingredient.
中の毒素を抽出せしめる抽出工程と；前記液体より不要
物を除去し、毒素を含有した清液を分離する清液生成工
程と；前記清液をフィルタに透過せしめ該フィルタ中に
毒素を捕獲せしめた後、フィルタより毒素を取出し毒素
のみを得る毒素生成工程と；前記毒素を調製して薬剤と
する調製工程と；から成ることを特徴とする河豚毒素を
有効成分とする薬剤の製造方法。(3) An extraction step of immersing the ovary of a fugu in a liquid and extracting toxins in the ovary into the liquid; and a liquid production step of removing unnecessary substances from the liquid and separating a liquid containing toxins. A toxin generation step in which the liquid is passed through a filter to trap toxins in the filter, and then the toxin is extracted from the filter to obtain only the toxin; A preparation step in which the toxin is prepared as a drug. A method for producing a drug containing a fugu toxin as an active ingredient, characterized by:
毒素を抽出せしめる抽出工程と；前記液体から不要固形
物を除去して第一次清液を分離する第一次清液生成工程
と；前記第一次清液に含有せしめられた蛋白を除去して
第二次清液を分離する第二次清液生成工程と；前記第二
次清液をフィルタに透過せしめ該フィルタ中に毒素を捕
獲せしめた後、該フィルタを酢酸液により洗浄すること
により毒素を含有した酢酸液を得る毒素溶液生成工程と
；前記毒素溶液を弱アルカリ性に調整して毒素と酢酸を
分離し、毒素のみを得る毒素生成工程と；前記毒素を調
製して薬剤とする調製工程と；から成ることを特徴とす
る河豚毒素を有効成分とする薬剤の製造方法。(4) An extraction step of immersing the ovaries of the fugu in a liquid and extracting toxins in the ovaries into the liquid; a primary liquid that removes unnecessary solids from the liquid and separates the primary liquid; a generation step; a second clear liquid generation step of removing proteins contained in the first clear liquid and separating a second clear liquid; passing the second clear liquid through a filter; a toxin solution generation step of obtaining an acetic acid solution containing the toxin by washing the filter with an acetic acid solution after capturing the toxin; adjusting the toxin solution to be slightly alkaline to separate the toxin and acetic acid; 1. A method for producing a drug containing fugu toxin as an active ingredient, comprising: a toxin generation step to obtain only the toxin; and a preparation step to prepare the toxin into a drug.
の毒素を液体中に抽出せしめた後、該液体より前記毒素
を分離することを特徴とする河豚毒素の抽出方法。(5) A method for extracting Fugu toxin, which comprises immersing the ovary of a Fugu in a liquid to extract the toxin in the ovary into the liquid, and then separating the toxin from the liquid.
中の毒素を抽出せしめる抽出工程と；前記液体より不要
物を除去し、毒素を含有した清液を分離する清液生成工
程と；前記清液をフィルタに透過せしめ該フィルタ中に
毒素を捕獲せしめた後、フィルタより毒素を取出し毒素
のみを得る毒素生成工程と；から成ることを特徴とする
河豚毒素の抽出方法。(6) An extraction step of immersing the ovaries of a fugu in a liquid and extracting toxins in the ovaries into the liquid; and a liquid production step of removing unnecessary substances from the liquid and separating a liquid containing toxins. A method for extracting a fugu toxin, comprising: a step of producing a toxin by passing the liquid through a filter to trap the toxin in the filter, and then extracting the toxin from the filter to obtain only the toxin.
毒素を抽出せしめる抽出工程と；前記液体から不要固形
物を除去して第一次清液を分離する第一次清液生成工程
と；前記第一次清液に含有せしめられた蛋白を除去して
第二次清液を分離する第二次清液生成工程と；前記第二
次清液をフィルタに透過せしめ該フィルタ中に毒素を捕
獲せしめた後、該フィルタを酢酸液により洗浄すること
により毒素を含有した酢酸液を得る毒素溶液生成工程と
；前記毒素溶液を弱アルカリ性に調整して毒素と酢酸を
分離し、毒素のみを得る毒素生成工程と；から成ること
を特徴とする河豚毒素の抽出方法。(7) An extraction step of immersing the ovary of a fugu in a liquid and extracting toxins in the ovary into the liquid; a primary liquid that removes unnecessary solids from the liquid and separates a primary liquid; a generation step; a second clear liquid generation step of removing proteins contained in the first clear liquid and separating a second clear liquid; passing the second clear liquid through a filter; a toxin solution generation step of obtaining an acetic acid solution containing the toxin by washing the filter with an acetic acid solution after capturing the toxin; adjusting the toxin solution to be slightly alkaline to separate the toxin and acetic acid; A method for extracting fugu toxin, comprising: a toxin generation step to obtain only the toxin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1293622A JPH03153627A (en) | 1989-11-11 | 1989-11-11 | Medicament containing swellfish poison as pharmaceutically effective component, its preparation and extraction of said swellfish poison |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1293622A JPH03153627A (en) | 1989-11-11 | 1989-11-11 | Medicament containing swellfish poison as pharmaceutically effective component, its preparation and extraction of said swellfish poison |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03153627A true JPH03153627A (en) | 1991-07-01 |
Family
ID=17797097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1293622A Pending JPH03153627A (en) | 1989-11-11 | 1989-11-11 | Medicament containing swellfish poison as pharmaceutically effective component, its preparation and extraction of said swellfish poison |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03153627A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0750909A4 (en) * | 1994-03-17 | 2000-07-26 | Nanning Maple Leaf Pharmaceuti | The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence |
| KR100537436B1 (en) * | 2001-05-31 | 2005-12-21 | 김익수 | Pharmaceutical composition comprising a swellfish extract for anticancer therapy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5594319A (en) * | 1979-01-09 | 1980-07-17 | Yoshio Otaka | Drug for external use consisting of liver oil of swellfish |
-
1989
- 1989-11-11 JP JP1293622A patent/JPH03153627A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5594319A (en) * | 1979-01-09 | 1980-07-17 | Yoshio Otaka | Drug for external use consisting of liver oil of swellfish |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0750909A4 (en) * | 1994-03-17 | 2000-07-26 | Nanning Maple Leaf Pharmaceuti | The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence |
| KR100537436B1 (en) * | 2001-05-31 | 2005-12-21 | 김익수 | Pharmaceutical composition comprising a swellfish extract for anticancer therapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3041803B2 (en) | Method for preparing an extract containing anthocyanosides with high purity from a plant or an extract thereof | |
| WO2006032510A1 (en) | Extracts from roots and/or shoots of asparagus officinalis l., their preparation and their use | |
| JPH04288019A (en) | Extract of gingko biloba leaves and use thereof | |
| CN100522990C (en) | Method of recovering protein from discarded matter of preparing alginate microcapsule | |
| WO2019080571A1 (en) | Method for extracting toosendanin | |
| CN108079022A (en) | A kind of hirudo extract and preparation method and application | |
| JPH03153627A (en) | Medicament containing swellfish poison as pharmaceutically effective component, its preparation and extraction of said swellfish poison | |
| JP4220426B2 (en) | Pharmaceutical composition for treating liver disease and method for producing the same | |
| CN108926561A (en) | Application of the jateorrhizine in prevention and treatment dementia or improvement memory class product | |
| CN110934899B (en) | Extraction method and application of blood coagulation and hemostasis active ingredients of eclipta alba | |
| CN1456257B (en) | Fresh motherwort particle preparing method | |
| CN109867603B (en) | Method for purifying chicoric acid | |
| JPH02207090A (en) | Extraction and concentration of ganglioside | |
| CN108451942A (en) | A kind of arginine glutamic acid injection pharmaceutical composition and preparation method thereof | |
| RU2005485C1 (en) | Method for production of medicine against animal skin diseases | |
| EP1338303B1 (en) | Detoxifying phytotherapeutic composition from two plant extracts and process for preparing the same | |
| JP2678617B2 (en) | Large garlic extract | |
| JPH0348167B2 (en) | ||
| JPS6227074B2 (en) | ||
| TWI524889B (en) | A method of manufacturing an herbal extract for wound healing and the herbal extract thereof | |
| CN101085014B (en) | Traditional Chinese medicinal composition containing red sage root, notoginseng, safflower and borneol or storax and its preparation | |
| CN1879660A (en) | A method for preparing novel chemical substance with anti-fertility and pain relieving activity | |
| SU577034A1 (en) | Method of preparing sesquiterpenic lactones | |
| US2035557A (en) | Hormone | |
| JPS5874613A (en) | Antiepileptic comtaining plant component |